Leber’s congenital amaurosis is a rare inherited eye condition that causes severe vision loss or blindness from birth or early infancy. While there is currently no cure, treatment options focus on helping children make the most of any remaining vision and, in select cases, gene therapy may restore some sight.

Hope Through Treatment: What Families Need to Know

When a baby is diagnosed with Leber’s congenital amaurosis, families naturally want to understand what can be done. The main goals of treatment are to support any remaining vision the child has, help them develop important life skills despite vision loss, and in some cases, use cutting-edge medical approaches to improve their ability to see. Treatment decisions depend on the type of genetic change causing the condition, how much vision the child has, and their age.^[1]

It’s important to know that standard treatments have been available for years to help children adapt and thrive. These include tools like special glasses and magnifiers, as well as training programs that teach children how to move around safely and do everyday tasks. Beyond these established approaches, researchers are actively testing new therapies in clinical trials. Some of these experimental treatments have already shown promise in restoring vision to children who were nearly blind since birth.^[2]

Every child with Leber’s congenital amaurosis is different. The specific gene that is changed affects how the disease behaves and which treatments might help. This is why genetic testing is such an important step after diagnosis. Knowing which gene is involved helps doctors recommend the best treatment plan and determine whether a child might benefit from newer therapies being studied in research settings.^[1]

Standard Treatment Approaches

For most children with Leber’s congenital amaurosis, standard treatment focuses on supporting their remaining vision and helping them develop skills for daily living. While these approaches don’t restore lost vision, they can make a significant difference in a child’s ability to function and participate in the world around them.^[2]

The most common support tools are called low vision aids. These are devices designed to help people with poor vision see better. For children with Leber’s congenital amaurosis, this might include eyeglasses with strong lenses, handheld magnifying glasses, or reading prisms. The specific aids recommended depend on how much vision the child has. Some children may also benefit from electronic devices or computer-based aids that enlarge text or images. These tools don’t fix the underlying problem with the retina, but they help children use whatever vision they have more effectively.^[2]

Beyond physical aids, many children benefit from orientation and mobility training. This type of training teaches children how to move around safely and independently despite their vision loss. The earlier this training begins, the better prepared children will be as they grow. Young children learn basic movement skills, while older children might learn to use a white cane or eventually work with a guide dog. Public transportation training is also important as children get older and want more independence.^[4]

Some children with Leber’s congenital amaurosis experience other eye problems that may need separate treatment. For example, some develop cataracts, which is a clouding of the lens inside the eye. Others may have keratoconus, where the clear front part of the eye becomes cone-shaped. While treating these additional problems won’t fix the underlying retinal disease, addressing them can help preserve whatever vision remains. An eye specialist can monitor for these complications and recommend treatment if needed.^[3]

Children with Leber’s congenital amaurosis also benefit from supportive services beyond direct eye care. Because vision loss can affect how children learn and develop, early intervention programs are crucial. These programs provide educational support and teach skills through hearing, touch, and other senses. Some children may also need psychological support to help them cope with the emotional challenges of vision loss, especially as they grow older and face situations like not being able to drive or experiencing bullying from peers.^[1]

The duration of standard treatment support is typically lifelong. Children will need regular follow-up with eye specialists to monitor their vision and adjust their aids as they grow. Mobility training and adaptive skills instruction often continue throughout childhood and into young adulthood, with new skills introduced as children reach different developmental stages.^[4]

Breakthrough Gene Therapy: A New Era of Treatment

In recent years, a remarkable new type of treatment has emerged for certain children with Leber’s congenital amaurosis. Gene therapy represents one of the most exciting advances in medicine, offering the possibility of actually improving vision rather than just supporting what remains. This approach works by introducing a healthy copy of a faulty gene directly into the cells of the retina, potentially correcting the underlying genetic problem causing the disease.^[5]

The most significant breakthrough came with the approval of voretigene neparvovec-rzyl, marketed under the brand name Luxturna. This was a historic moment: it became the first gene therapy approved by the US Food and Drug Administration to treat any disease. Luxturna is specifically designed for patients with Leber’s congenital amaurosis caused by mutations in both copies of the RPE65 gene. This particular genetic form accounts for about six percent of all Leber’s congenital amaurosis cases.^[5]

The RPE65 gene provides instructions for making a protein that is essential for vision. Without this protein working properly, the photoreceptor cells in the retina cannot function correctly. When someone receives Luxturna, a surgeon injects the therapy underneath the retina during a procedure called a vitrectomy. This is a common type of retina surgery, but it requires an ophthalmologist with special experience in administering gene therapy. The healthy gene is carried into the retinal cells by a modified virus that has been made harmless. Once inside the cells, the new gene begins producing the missing protein.^[8]

Clinical trials of Luxturna showed remarkable results. Patients who received the treatment showed improvement in their ability to navigate an obstacle course in dim lighting conditions, a test called multi-luminance mobility testing. While the gene therapy doesn’t completely restore normal vision, the improvements can be life-changing for patients who had extreme vision loss. Some children who were nearly blind from birth could see stars for the first time or identify objects around them. The visual improvements have remained stable for at least several years after treatment, though long-term data is still being collected since this therapy is relatively new.^[8]

Beyond RPE65, researchers are actively working on gene therapies for other genetic forms of Leber’s congenital amaurosis. Clinical trials are underway for LCA caused by mutations in other genes. For example, gene therapy for LCA5, one of the most severe forms of the condition, has shown vision improvements in early clinical trials. Some patients who had been almost totally blind since birth gained the ability to see and identify objects for the first time. The company developing this therapy planned to enroll children in the trial, recognizing that earlier treatment might provide even better results.^[11]

Another promising approach involves gene therapy for LCA4, caused by mutations in the AIPL1 gene. Clinical trials in London treated children between the ages of one and four, and results showed significant vision improvements. This work suggests that gene therapy may be effective even in very young children, potentially preserving vision before extensive damage occurs. Researchers are working toward seeking approval for this therapy in the United Kingdom.^[11]

Gene therapy for LCA1, caused by mutations in the GUCY2D gene, is also being studied. Early results from clinical trials have been encouraging, offering hope to families affected by this particular genetic form. As research continues, scientists are working to develop gene therapies targeting the many different genes that can cause Leber’s congenital amaurosis.^[11]

Not all types of gene therapy involve directly replacing a gene. Some approaches use RNA therapies, which work differently. One example is sepofarsen, designed for people with LCA10 caused by a specific mutation in the CEP290 gene (the IVS26 mutation). This therapy uses what’s called an antisense oligonucleotide, which is a small piece of genetic material that can modify how genes are read by cells. Clinical trials for sepofarsen showed effectiveness in earlier testing and have now advanced to Phase 3 trials, the final stage before potential approval. Phase 3 trials compare the new treatment against current standard approaches in larger groups of patients.^[11]

The safety profile of gene therapy for Leber’s congenital amaurosis has been generally positive. Clinical trials have shown that the treatment is safe through at least 1.5 years after administration, with visual improvements remaining stable over time. Because the therapy requires surgery, there are normal surgical risks involved, but these are manageable with an experienced surgical team. Long-term safety continues to be monitored as more patients receive treatment and more time passes since the first treatments were given.^[10]

Clinical trials for various gene therapies are taking place in multiple locations, including the United States, Europe, and the United Kingdom. Patient eligibility varies depending on the specific trial and genetic form of the disease. Generally, patients need to have confirmed genetic testing showing they have the specific mutation being targeted by that trial. Some trials have age requirements, and doctors must confirm that patients still have living retinal cells that could benefit from treatment. Families interested in clinical trials should work with their child’s eye specialist to explore available opportunities.^[11]

Most Common Treatment Methods

• Low Vision Aids
  • Eyeglasses with strong corrective lenses to help maximize remaining vision
  • Magnifying glasses and handheld magnifiers for reading and close-up tasks
  • Reading prisms to help with specific visual tasks
  • Electronic devices and computer-based aids that enlarge text or images
  • Optical aids customized to each child’s specific level of remaining vision
• Orientation and Mobility Training
  • Early movement skills training for infants and toddlers
  • White cane training for safe independent navigation
  • Guide dog services for older children and adults
  • Public transportation route training
  • Adaptive training skills for daily living activities
• Gene Therapy
  • Voretigene neparvovec-rzyl (Luxturna) for RPE65 gene mutations, delivered through subretinal injection during vitrectomy surgery
  • Experimental gene therapies for LCA5 caused by RPGRIP1 mutations, currently in Phase 1/2 clinical trials
  • Gene therapy for LCA4 caused by AIPL1 mutations, showing promising results in children ages one to four
  • Gene therapy for LCA1 caused by GUCY2D mutations, currently being evaluated in clinical trials
  • RNA therapy (sepofarsen) for LCA10 caused by specific CEP290 gene mutations, advancing to Phase 3 trials
• Supportive Services
  • Early educational intervention programs focused on non-visual learning
  • Psychological counseling and mental health support for coping with vision loss
  • Adaptive skills training for school and work activities
  • Job placement assistance through vocational rehabilitation services
  • Genetic counseling for families to understand inheritance and risks
• Treatment of Associated Eye Conditions
  • Cataract surgery when clouding of the lens develops
  • Management of keratoconus (cone-shaped cornea)
  • Monitoring and treatment for abnormal pupil responses
  • Regular eye examinations to detect and treat secondary complications